L-Asparagine
|
Basic information |
| Metabolite name | L-Asparagine |
 | HMDB0000168 |
 |
C00152 |
 |
6267 |
| Synonyms | Asparagines; |
| No. of studies | 46 |
|
Basic information |
| Metabolite name | L-Asparagine |
| HMDB0000168 |
|
C00152 |
|
6267 |
| Synonyms | Asparagines; |
| No. of studies | 46 |
|
Relationship between L-Asparagine and depression (count: 46) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M010 | Type4 | SSRI-treated responder group vs. non-responder group | Plasma | Human | Up |
| Study M016 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M042 | Type3 | fluoxetine group vs. control group | Plasma | Rhesus monkey | Up |
| Study M051 | Type3 | fluoxetine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M065 | Type2 | depressed group at 6-weeks treatment vs. baseline | Plasma | Human | Up |
| Study M067 | Type1 | naturally-occurring depression group vs. control group | Serum | Cynomolgus monkey | Down |
| Study M082 | Type3 | medium dose of DG group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M082 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M083 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M092 | Type1 | LPS group vs. control group | Prefrontal cortex | CD-1 mouse | Up |
| Study M105 | Type1 | sCSDS group vs. control group | Liver | C57BL/6JJmsSlc mouse | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Up |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Up |
| Study M110 | Type1 | SD group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M111 | Type3 | WT-Scop group vs. WT-Veh group | Plasma | C57BL/6 mouse | Down |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M130 | Type2 | CSDS + DG group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M131 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M132 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M207 | Type1 | depressed group vs. control group | Hippocampus | Kunming mouse | Up |
| Study M207 | Type1 | depressed group vs. control group | Faece | Kunming mouse | Down |
| Study M209 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M458 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M463 | Type3 | DG group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M480 | Type2 | CGA-treated group vs. sleep deprivation group | Urine | Wistar rat | Down |
| Study M492 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Down |
| Study M492 | Type2 | ACTH + memantine group vs. ACTH group | Urine | Wistar rat | Up |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M633 | Type2 | corticosterone + Chrysanthemum morifolium group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M636 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M636 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Faece | Sprague-Dawley rat | Down |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, discovery cohort | Plasma | Human | Down |
| Study M693 | Type1 | SDS group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M788 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + Gleditsiae spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M873 | Type1 | ovariectomy + CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M896 | Type1 | eating disorders with MDD group vs. eating disorders without MDD group | Plasma | Human | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |
| Study M909 | Type3 | ketamine group vs. control group | Hippocampus | CD-1 mouse | Down |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M953 | Type1 | CRS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M972 | Type1 | CRS + irradiation group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M972 | Type2 | CRS + irradiation + Paeoniae Radix Alba group vs. CRS + irradiation group | Serum | Sprague-Dawley rat | Up |
| Study M972 | Type2 | CRS + irradiation + paeoniflorin group vs. CRS + irradiation group | Serum | Sprague-Dawley rat | Up |